Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei

J Surg Res. 2022 Jun:274:68-76. doi: 10.1016/j.jss.2022.01.001. Epub 2022 Feb 3.

Abstract

Introduction: The pathologic classification of pseudomyxoma peritonei is controversial. This study aimed to standardize the histopathological evaluation of pseudomyxoma peritonei and identify the clinicopathological factors associated with survival.

Methods: A pathologic review was performed to systematize the pathology report and verify the relationship between clinical features and survival. Terminology was based on the World Health Organization and Peritoneal Surface Oncology Group International definitions. Preoperative serum levels of carcinoembryonic antigen, CA19-9, and CA-125 were evaluated to determine their association with overall survival (OS) and ability to predict CC0-1 cytoreduction.

Results: Among 109 patients with carcinomas resulting from primary appendiceal neoplasms, 72 had pseudomyxoma peritonei of appendiceal origin and underwent debulking surgery. CC0-1 cytoreduction and CC2-3 cytoreduction were achieved in 61% and 39% of patients, respectively. Patients in the CC0-1 and CC2-3 groups had an OS of 122.80 and 32.92 mo, respectively. The histologic grade was associated with CC0-1 cytoreduction; however, it did not influence OS. Patients with CC0-1 cytoreduction, acellular mucin, and low-grade lesions had better disease-free survival. Higher preoperative CA19-9 levels were associated with poor OS. Normal carcinoembryonic antigen values were associated with 100% sensitivity for predicting CC0-1. CA19-9 levels of 625 U/mL were associated with a low possibility of predicting CC0-1.

Conclusions: Histologic grades are associated with disease-free survival when CC0-1 cytoreduction is achieved. Normal preoperative CA19-9 levels were associated with a better OS. CC0-1 cytoreduction is the main determinant of longer survival.

Keywords: CA-125 antigen; CA-19-9 antigen; Carcinoembryonic antigen; Cytoreductive surgery; Pseudomyxoma peritonei.

MeSH terms

  • Appendiceal Neoplasms* / pathology
  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • Carcinoembryonic Antigen
  • Cytoreduction Surgical Procedures / methods
  • Humans
  • Hyperthermia, Induced* / methods
  • Peritoneal Neoplasms* / diagnosis
  • Peritoneal Neoplasms* / surgery
  • Prognosis
  • Pseudomyxoma Peritonei* / diagnosis
  • Pseudomyxoma Peritonei* / pathology
  • Pseudomyxoma Peritonei* / surgery

Substances

  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • Carcinoembryonic Antigen